Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Zeyuan Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7814-5416; OpenAlex author ID A5115603598. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2021: 3 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. UBE2T-Driven p53 Degradation Rewires Glycolysis to Orchestrate Lactylation-Mediated CAFs Activation and ECM Deposition in Pancreatic Cancer. Co-author DOI 10.1002/advs.202514933↗
  2. USP20 promotes CD8+ T cell exhaustion and impairs KRAS G12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2026-338277↗
  3. KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Co-author DOI 10.1016/j.xcrm.2025.101966↗
  4. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Co-author DOI 10.1053/j.gastro.2023.02.025↗
  5. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-021-08769-6↗
  6. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma Last author DOI 10.21203/rs.3.rs-148631/v1↗
  7. Comprehensive Analysis of the Transcriptional Expressions and Prognostic Value of S100A Family in Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-149466/v1↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiangyan Jiang · 7 shared papers, 2021–2026 · strength 1.21
  2. Zuoyi Jiao · 4 shared papers, 2023–2026 · strength 0.80
  3. Yong Ma · 4 shared papers, 2021–2026 · strength 0.75
  4. Hongbin Li · 3 shared papers, 2021 · strength 0.41
  5. Tao Wang · 2 shared papers, 2023–2025 · strength 0.33
  6. Junhong Guan · 2 shared papers, 2023–2025 · strength 0.33
  7. Rufu Chen · 1 shared paper, 2026 · strength 0.23
  8. Yuman Dong · 1 shared paper, 2025 · strength 0.18
  9. Lei Zhao · 1 shared paper, 2021 · strength 0.14
  10. Леи Жао · 1 shared paper, 2021 · strength 0.14
  11. Yong Ma · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.